CTLA4 and neoplasm: In the in vivo antitumor study, the DOX/anti-CTLA-4/anti-PD-1 co-loaded hydrogel caused higher tumor inhibition efficiency, prolonged mice survival time and increased infiltration of CD8+ T cells in tumors, compared with the hydrogel loaded with DOX or antibodies only.